Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas
Authors:
- Muna QayedMQMuna Qayed
- Pam BrillPBPam Brill
- Melissa MartinMMMelissa Martin
- Karen Wasilewski‐MaskerKWKaren Wasilewski‐Masker
- Howard M. KatzensteinHKHoward M. Katzenstein
- 2 February 2012
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 59 (5) , 854-858
Abstract
Background: Patients with relapsed pediatric sarcomas have a poor outcome and are in need of novel effective therapies.Methods: We retrospectively reviewed the records of patients at Children's Healthcare of Atlanta who were treated with gemcitabine (675 mg/m2) intravenously (IV) on Day 1 and Day 8, and docetaxel (75 mg/m2) IV on Day 8, repeated every 3 weeks.Results: Nineteen patients with a median age of 11 years were treated from 2006–2010 and received 123 total courses. Two patients (11%), both with rhabdomyosarcoma, demonstrated objectives responses [one complete response (CR) and one partial response (PR)]. Seven other patients (39%) had stable disease (SD). The 1‐year progression‐free survival (PFS) of the entire cohort was 24% ± 10% with a median time to progression of 2 months (range: 0.5–14 months). The 1‐year overall survival (OS) was 43% ± 11%. Grade 3 or 4 toxicities occurred in 14 patients (74%) and 52 courses (42%), and were most commonly hematologic (neutropenia = 37, anemia = 17, and thrombocytopenia = 23 courses).Conclusions: The dismal outcomes for patients with relapsed and refractory sarcomas and the lack of effective sarcoma salvage regimens highlight the need for new approaches. This report of the therapeutic activity of gemcitabine and docetaxel (GEMDOX) in rhabdomyosarcoma and other pediatric reports describing activity in osteosarcoma and Ewing sarcoma suggest that this combination should be considered for formal evaluation in a pediatric specific clinical trial. At a minimum, it appears to offer a reasonable, tolerable, palliative option. Pediatr Blood Cancer 2012; 59: 854–858.Keywords
Funding Information
- Carter Samuel Martin Experimental Therapy Research Fund
This publication has 8 references indexed in Scilit:
- Treatment of Relapsed/Refractory Pediatric Sarcomas With Gemcitabine and DocetaxelJournal of Pediatric Hematology/Oncology, 2009
- Prognostic factors and outcomes for osteosarcoma: An international collaborationEuropean Journal of Cancer, 2009
- Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcomaCancer, 2008
- Changes in Incidence and Survival of Ewing Sarcoma Patients Over the Past 3 DecadesJournal of Pediatric Hematology/Oncology, 2008
- Phase II investigation of docetaxel in pediatric patients with recurrent solid tumorsCancer, 2006
- Long‐term survival probabilities for childhood rhabdomyosarcomaCancer, 2005
- Phase I Trial and Pharmacokinetics of Gemcitabine in Children With Advanced Solid TumorsJournal of Clinical Oncology, 2004
- Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II TrialJournal of Clinical Oncology, 2002